Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...
BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 115
- Registration Number
- NCT00458861
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
BIIB014 Phase 2a Monotherapy
- Conditions
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Registration Number
- NCT00451815
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1417
- Registration Number
- NCT00451451
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT00442780
- Locations
- 🇷🇸
Research Sites, Belgrade, Serbia
🇷🇸Research Site, Belgrade, Serbia
Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2009-07-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 83
- Registration Number
- NCT00438607
- Locations
- 🇮🇳
Research Sites, Bangalore, India
🇬🇧Research Site, Salford, United Kingdom
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
- Conditions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-09-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT00424788
- Locations
- 🇺🇸
Cleveland Clinic Mellen Center for MS, Cleveland, Ohio, United States
🇺🇸Center for Neurological Disorders, Aurora Health Care, Milwaukee, Wisconsin, United States
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1234
- Registration Number
- NCT00420212
- Locations
- 🇻🇮
Research Site, Vienna, Virgin Islands (U.S.)
CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT00412412
- Locations
- 🇺🇸
Research Site, New York, New York, United States
🇺🇸Research site, Houston, Texas, United States
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 627
- Registration Number
- NCT00391066
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 621
- Registration Number
- NCT00390221
- Locations
- 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom